摘要
目的:为了进一步研究和比较临床治疗新生儿呼吸窘迫综合征(NRDS)过程中采用不同剂量猪肺磷脂注射液(固尔苏)联合鼻塞式管道正压通气((Nasal Continuous Positive Airway Pressure,NCPAP)治疗的临床疗效差异,从而为临床实践提供借鉴和参考。方法:本文以我院2010年12月~2013年1月期间入院治疗的92例新生儿呼吸窘迫综合征患儿为研究对象,对患儿的临床资料进行了回顾性分析。结果:在PaO2和PaCO2两项指标组间比较,治疗组患儿的水平均显著的优于对照组的水平,且组间比较,P均〈0.05,差异具有统计学意义;在平均通气时间和吸氧时间两项指标组间比较,治疗组患儿的两项时间均显著的低于对照组患儿的时间,且组间比较,P均〈0.05,差异具有统计学意义。结论:在临床治疗新生儿呼吸窘迫综合征的过程中,采用剂量固尔苏(首次剂量为200mg/kg)联合NCPAP治疗方法的临床实践效果显著,是临床治疗新生儿呼吸窘迫综合征的安全可靠选择。
Objective:To study and compare the differences of the clinical efficacy for different doses of Curosurf joint NCPAP in the treatment of neonatal respiratory distress syndrome and provide reference for clinical practice.Methods:92 cases of neonatal respiratory distress syndrome in children hospitalized in our hospital from December 2010 to January 2013 were chosen as the research object.The clinical data of the children was taken for retrospective analysis.Results:In the comparison between two indicators of PaO2 and PaCO2group,the level in the treatment group was significantly better than the control group,and between the two groups,P〈0.05,the differences were statistically significant.In the comparison of average ventilation time and oxygen time group,the time of the treatment group were significantly lower than the control group children,and the comparison between groups,P〈0.05,the difference was statistically significant.Conclusion:In the clinical treatment of neonatal respiratory distress syndrome,the clinical effect of the application of dose of Curosurf(the first dose of 200mg/kg) United NCPAP is significant,and it is the safe and reliable choice of the clinical treatment of neonatal respiratory distress syndrome.
出处
《中国医药导刊》
2014年第6期1022-1023,共2页
Chinese Journal of Medicinal Guide